Insud Pharma announced today that it has entered into an agreement with Fresenius Kabi. Under the terms of the agreement Fresenius Kabi will acquire 55% of mAbxience, the global fully-fledged biotech company of the Spanish group.
Insud Pharma and Fresenius Kabi combine efforts to accelerate the growth of mAbxience
![thehealthco](https://thehealthco.info/wp-content/uploads/2021/09/how-the-pandemic-changed-families-views-on-pediatric-telehealth-care.jpg)